细胞周期蛋白依赖性激酶4/6抑制剂的研究进展(5)
[20] Finn RS， Dering J， Conklin D， et al. PD 0332991， a selective cyclin D kinase 4/6 inhibitor， preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro [J/OL]. Breast Cancer Res，2009， 11(5)： R77 [2020-03-21]. doi： 10.1186/bcr2419.[21] Finn RS， Crown JP， Lang I， et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive ......
您现在查看是摘要页，全文长 3045 字符。